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RESEARCH ARTICLE
Lysyl oxidases regulate fibrillar collagen remodelling in idiopathic
pulmonary fibrosis
Gavin Tjin1,2,3,4,*, Eric S. White5, Alen Faiz6,7,8, Delphine Sicard9, Daniel J. Tschumperlin9, Annabelle Mahar10,
Eleanor P. W. Kable3 and Janette K. Burgess1,2,7,8,11,*
ABSTRACT
Idiopathic pulmonary fibrosis (IPF) is a progressive scarring disease of
the lungwith feweffective therapeutic options. Structural remodelling of
the extracellular matrix [i.e. collagen cross-linkingmediated by the lysyl
oxidase (LO) family of enzymes (LOX, LOXL1-4)] might contribute to
disease pathogenesis and represent a therapeutic target. This study
aimed to further our understanding of the mechanisms by which LO
inhibitors might improve lung fibrosis. Lung tissues from IPF and non-
IPF subjects were examined for collagen structure (second harmonic
generation imaging) and LO gene (microarray analysis) and protein
(immunohistochemistry and western blotting) levels. Functional effects
(collagen structure and tissue stiffness using atomic force microscopy)
of LO inhibitors on collagen remodelling were examined in twomodels,
collagen hydrogels and decellularized human lung matrices. LOXL1/
LOXL2 gene expression and protein levels were increased in IPF
versus non-IPF. Increased collagen fibril thickness in IPF versus
non-IPF lung tissues correlated with increased LOXL1/LOXL2, and
decreased LOX, protein expression. β-Aminoproprionitrile (β-APN;
pan-LO inhibitor) but not Compound A (LOXL2-specific inhibitor)
interfered with transforming growth factor-β-induced collagen
remodelling in both models. The β-APN treatment group was tested
further, and β-APN was found to interfere with stiffening in the
decellularized matrix model. LOXL1 activity might drive collagen
remodelling in IPF lungs. The interrelationship between collagen
structural remodelling and LOs is disrupted in IPF lungs. Inhibition of
LO activity alleviates fibrosis by limiting fibrillar collagen cross-linking,
thereby potentially impeding the formation of a pathological
microenvironment in IPF.
KEY WORDS: Idiopathic pulmonary fibrosis, Extracellular matrix,
Collagen, Lysyl oxidase, Second harmonic generation
INTRODUCTION
Idiopathic pulmonary fibrosis (IPF) is a specific form of progressive
fibrosing lung disease of unknown cause that leads to chronic
respiratory failure and death (Raghu et al., 2011), with a median
survival of ∼3 years after diagnosis (Demedts et al., 2001). IPF is a
subcategory under the general disease category of interstitial lung
disease (ILD). Common traits of ILDs are the presence of
inflammation and pulmonary fibrosis. IPF patients have a poor
prognosis, with 44% mortality rate for IPF patients expected within
5 years, compared with the mortality rates in two other ILDs, ILD-
associated connective tissue disease (33%) and pulmonary
sarcoidosis (2%) (Demedts et al., 2001).
Like many fibrotic disorders, IPF is characterized by enhanced
deposition and remodelling of the extracellular matrix (ECM).
Although data are emerging about the altered composition of the
ECM in IPF (Booth et al., 2012; Estany et al., 2014; Kuhn et al., 1989;
Kuhn and McDonald, 1991; Ward and Hunninghake, 1998), less is
known about the structural changes that occur in collagens in this
disease. Collagens undergo extensive post-translational modifications,
including formation of cross-links between fibres that stabilize the
molecules and generate a strong collagen fibril, which provides tensile
strength. Aberrant cross-linking is known to contribute to increased
tissue stiffness, a pathological characteristic of IPF (Clarke et al., 2013).
Fibrillar collagen structures (predominantly collagens I and III)
can be visualized and quantified using second harmonic generation
(SHG) microscopy (Abraham et al., 2012; Tjin et al., 2014). SHG
imaging has been used to analyse ECM structures in biological
systems in vitro, ex vivo and in vivo (Brown et al., 2003; Caetano-
Lopes et al., 2010; Cox et al., 2003; Guo et al., 1999; Nadiarnykh
et al., 2007; Sivaguru et al., 2010; Suzuki et al., 2012; Williams
et al., 2001) and can semi-quantitatively measure the ratio of
mature organized collagen to immature disorganized collagen
fibrils (Williams et al., 2005). This technique, therefore, enables
comparisons of collagen rearrangement in tissues, analysis of
collagen structure (Caetano-Lopes et al., 2010; Nadiarnykh et al.,
2007; Sivaguru et al., 2010; Suzuki et al., 2012) and even
measurement of the thickness of the fibres (Chu et al., 2007). We
have recently reported the robustness of this technique to quantify
fibrillar collagen I remodelling in airway tissues in chronic
obstructive pulmonary disease (Tjin et al., 2014).
Maturity of collagen fibres and thus the mechanical properties of
the fibres are dependent on the level of intermolecular cross-linking.Received 11 April 2017; Accepted 16 August 2017
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Although the intermolecular fibrillar organization and certain
cross-linking processes can happen spontaneously, enzymes such
as lysyl oxidases (LOs) are necessary for further cross-linking. The
LO family of enzymes consists of five known paralogues: lysyl
oxidase (LOX) and LOX like 1-4 (LOXL1-4). During normal
development, the expression of LOs is tightly regulated, with
aberrant expression and activity being associated with pathological
manifestation in various diseases, including cancer (Erler et al.,
2006; Payne et al., 2005) and, as recently discovered, IPF (Aumiller
et al., 2017; Barry-Hamilton et al., 2010).
Collagen cross-linking contributes to the stiffness of the ECM of
tissues and is tightly regulated in normal tissue homeostasis.
However, in diseased tissue, aberrant cross-linking could lead to
the development of a pathological microenvironment. The stiffness of
the ECM influences the behaviour and function of cells within its
vicinity, including an increase in fibroblast proliferation and
contraction (Balestrini et al., 2012; Marinkovic et al., 2013). In
addition, a stiffer ECM leads to an increase in latent transforming
growth factor-β (TGF-β) activation (Burgess et al., 2016; Shi et al.,
2011; Wipff et al., 2007). In IPF, the lung tissue has a stiffness of
16.52±2.25 kPa, as opposed to 1.96±0.13 kPa in healthy lung tissue
(Booth et al., 2012). A stiffer matrix also promotes IPF-like
phenotypes, such as enhanced differentiation, proliferation and
resistance to apoptosis in non-IPF fibroblasts (Liu et al., 2010;
Marinkovic et al., 2012; Paszek et al., 2005; Wipff et al., 2007).
Despite the availability of two recently approved drugs for slowing
the progress of IPF [nintedanib (Mazzei et al., 2015; Richeldi et al.,
2014a,b) and pirfenidone (King et al., 2014; Valeyre et al., 2014)],
their associated incidence of side effects and modest clinical benefit
warrants further investigation into possible new therapeutic directions
for IPF (Moodley et al., 2015). Selective inhibition of LOXL2 activity
was recently investigated as a therapeutic approach for IPF [Barry-
Hamilton et al., 2010; ClinicalTrials.gov NCT01769196 (Raghu
et al., 2017)]. Although this trial was terminated early because of lack
of efficacy, there is still potential for the development of effective LO
inhibitors for targeting fibrosis. To enhance understanding of the
mechanisms by which LOX and LOXL enzyme inhibition might be
beneficial in IPF, this study aimed to investigate fibrillar collagen
structural remodelling in IPF lung tissues and to determine the
expression profile of LOs in IPF. It also investigated the effectiveness
of pan-LO and selective LOXL2 inhibition on fibrillar collagen
structural remodelling and tissue stiffness in the context of IPF.
RESULTS
Increased fibrillar collagen maturity/organization in IPF
lung tissues
To investigate the collagen structural remodelling in IPF, SHG
microscopy was performed on lung tissue sections from non-IPF
and IPF subjects. The SHG forward (F) signal is predominantly
from mature/organized fibrillar collagen, whereas the backward (B)
signal is from immature/disorganized fibrillar collagen. Thus,
increased F/B area corresponds to increased amounts of mature/
immature collagen, whereas increased F/B intensity ratios
correspond to an increased degree of collagen maturity/thickness
and vice versa (Tjin et al., 2014). Quantification of SHG images
showed that IPF lung parenchymal tissue had greater levels of
fibrillar collagen maturity/organization compared with the non-IPF
tissues (Fig. 1A,B). By contrast, the collagen structural organization
was not different between IPF and non-IPF ILD tissues (Fig. S1).
Lysyl oxidase genes were differentially expressed in IPF and
healthy control lung tissues
Fibrillar collagen maturity is catalysed by the LO family of
enzymes. To investigate the levels of LO enzymes in lung tissues,
lung tissue gene expression profiles of IPF and healthy controls
were analysed from two publically available data sets (Table 1).
LOXL1 gene expression was increased in IPF lung tissue compared
with healthy controls in two independent studies [false discovery
rate (FDR) adjusted P-value <0.25], whereas the LOXL2 gene
expression was increased in IPF lung tissue in a single data set. No
differences were found in LOX gene expression levels.
Lysyl oxidase protein levels were differentially expressed
between IPF and non-diseased lung tissues
To confirm the findings from the gene expression study, tissue
sections from the same samples used for the examination of
collagen structural organization were examined for LOX, LOXL1
and LOXL2 protein levels. Quantification of the captured images of
the stained lung tissue sections showed that LOX percentage surface
area and density were decreased in IPF compared with non-IPF,
whereas the percentage surface area and density of LOXL1 was
increased in IPF compared with non-IPF tissues (Table 2;
representative images in Fig. 2A). In agreement with prior studies
(Aumiller et al., 2017; Barry-Hamilton et al., 2010), LOXL2 density
was also increased in IPF compared with non-IPF tissues. By
Fig. 1. Increased level of collagen organization/maturity in IPF lung parenchyma. (A) Representative SHG images of lung parenchyma from non-IPF (n=7;
open circles) and IPF (n=8; filled diamonds) subjects (average of three or four samples per subject; yellow indicates backward immature/disorganized
collagen; cyan indicatesmature/organized collagen; scale bar: 100 µm). Brightness and contrast have been enhanced for display purposes only andwere applied
equally for all images. (B) Image analysis quantification of SHG intensity forward/backward signal ratio (intensity F/B; each point represents the mean of
three or four lung parenchymal samples per subject); a higher ratio indicates higher proportion of organized/mature fibrillar collagen. Data were analysed with
Student’s two-tailed parametric unpaired t-test. Data are presented as means±s.d. Data were obtained from one experimental replicate per subject. *P<0.05.
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contrast, only LOXL1, but not LOX or LOXL2, density increased in
IPF compared with non-IPF ILD (Table S1). In vitro, primary
human lung parenchymal fibroblasts from IPF patients produced
significantly greater levels of LOXL2 but not LOX or LOXL1 in the
cell lysate compared with non-IPF controls (Fig. S2A,B).
Expression of LOs was correlated with collagen remodelling
in lung tissues
To begin to understand the relationship between LOs and collagen
structural arrangement in lung tissues, we used correlation analysis.
The data from both non-IPF and IPF subjects were combined in the
correlation studies to examine the whole spectrum of collagen
remodelling in both cohorts. There was a positive correlation
between both LOXL1 (Table 3; Fig. S3) and LOXL2 (Table 3) with
collagen remodelling (SHG F/B ratios), whereas there was a
negative correlation between LOX and SHG forward to backward
signal (F/B) ratios (Table 3). LOXL1 positively correlated with
LOXL2, whereas LOX negatively correlated with both LOXL1 and
LOXL2 (Table 3).
Lysyl oxidase family members were differentially expressed
in IPF
The ratio of LOX/LOXL1 (Fig. 2B) and LOX/LOXL2 (Fig. S4)
densities and LOX/LOXL1 percentage surface areas were
significantly decreased in IPF lung tissue samples compared with
non-IPF subjects (Fig. 2B; Fig. S4). The ratio of LOX/LOXL1
percentage surface area inversely correlated with collagen maturity/
organization (F/B; Fig. 2C). There was no significant difference in
the ratios of LO family enzymes in the tissues of IPF and non-IPF
ILD subjects (Fig. S5; P=NS).
Collagen organization and LOX enzymes interrelate
differently in IPF
Given that LOX, LOXL1 and LOXL2 were differentially expressed
in IPF compared with non-IPF (Fig. 2B,C) and the expression of
these enzymes also correlated strongly with collagen remodelling
(Table 3), it was important to understand the interrelationship
between these parameters in IPF. Visualization of the three-
dimensional (3D) association among these variables showed spatial
separations between the variables in IPF compared with non-IPF
(Fig. 2D). We next performed factor analysis to investigate the
number of relationship groups (factors) accounting for the structure
of these associations. A minimum of two groups were required to
explain the associations within the data set (Fig. 2E), and Table S2
shows the strength of the contribution of the variables [LOX,
LOXL1, LOXL2, immunohistochemistry (IHC) data and SHG data]
to the two relationship groups. The strengths of contributions of the
variables were used to determine the weighted average values for
each relationship group (Fig. 2F,G). The values for relationship
Groups 1 and 2were significantly different between non-IPFand IPF,
indicating a difference in the relationships between the variables
(LOX, LOXL1, LOXL2 IHC data and SHG data) in disease.
Inhibition of LO activity reduced TGF-β-induced collagen
remodelling in collagen I hydrogels
To confirm the role of LO enzymes in fibrillar collagen remodelling,
3D in vitro cell culture experiments using inhibitors of LO activity
were performed. β-APN is a non-selective inhibitor of LO activity,
whereas Compound A is a specific inhibitor of LOXL2 activity
(Schilter et al., 2014). Pan-inhibition of LO activity, but not
inhibition of LOXL2-specific activity, reduced TGF-β-induced
collagen remodelling in collagen hydrogel fibroblast cultures
(Fig. 3). TGF-β increased the deposition of mature fibrillar
collagen by non-IPF fibroblasts but not IPF fibroblasts, which
was alleviated by the pan-LO inhibitor β-APN (Fig. 3D), but TGF-β
did not affect collagen fibre maturity/thickness (Fig. 3E). By
contrast, Compound A did not alleviate the increased deposition of
mature collagen compared with immature collagen, from both
fibroblast groups, induced by TGF-β, but on the contrary, increased
it (Fig. 3F). Compound A did reduce the thickness of the fibres
generated by the IPF fibroblasts in the presence and absence of
TGF-β stimulation (Fig. 3G).
Inhibition of LO activity reduced TGF-β-induced collagen
remodelling in reseeded decellularized matrices
To model the in vivo cell ECM interactions more closely, we used
decellularized human IPF and non-IPF lung scaffolds. There were
significantly more primary human lung fibroblasts remaining in the
supernatant after reseeding of the IPFmatrices compared with the non-
IPF matrices (Fig. 4A), potentially indicating higher cell attachment to
the non-IPF matrix. This was supported by histological staining of the
reseeded matrices, which showed that fewer cells were detectable in
the IPF matrix post-reseeding, compared with the non-IPF matrix
(Fig. 4B). Given the sparsity of cellular attachment in the IPF matrices,
these matrices were not examined further.
The non-IPF cells increased the maturity/thickness of the
collagen fibres in the non-IPF matrix in the presence of TGF-β
(Fig. 4C,D) but did not increase the amount of mature collagen




versus IPF) P-value FDR Data set
ILMN_11693 1.04 8.05×10−1 0.97 GSE48149
LOX 215446_s_at 0.87 3.71×10−1 0.59 GSE24206
204298_s_at 0.92 6.26×10−1 0.79 GSE24206
213640_s_at 0.96 6.57×10−1 0.81 GSE24206
LOXL1 ILMN_7655 1.39 5.21×10−3 0.11 GSE48149
203570_at 2.51 4.81×10−4 0.02 GSE24206
LOXL2 ILMN_22633 1.03 7.17×10−1 0.96 GSE48149
202998_s_at 1.57 2.11×10−2 0.13 GSE24206
228808_s_at 0.92 2.42×10−1 0.47 GSE24206
202999_s_at 0.93 3.57×10−1 0.58 GSE24206
202997_s_at 1.04 6.64×10−1 0.81 GSE24206
FDR, false discovery rate.
Table 2. Lysyl oxidase enzymes are differentially expressed in IPF lung
tissues
Non-IPF IPF
Image analysis Mean±s.d. Mean±s.d. P-value
LOX % Surface area 95.58±3.23 87.17±7.12 ↓ 0.009*†
Density 211.10±10.07 193.20±9.90 ↓ 0.016*
LOXL1 % Surface area 66.54±13.20 79.86±10.28 ↑ 0.033*
Density 171.80±16.56 188.90±12.14 ↑ 0.027*
LOXL2 % Surface area 50.84±23.76 66.86±9.85 0.094
Density 134.30±14.05 153.00±5.76 ↑ 0.003*
Quantification of immunohistochemical staining of the lung tissues using
image analysis on whole tissue. Data are presented as the percentage of the
surface area (% Surface area) stained with the protein of interest and density of
staining within the stained surface areas, comparing non-IPF (n=10) and IPF
(n=8) subjects. Data were analysed with Student’s two-tailed parametric
unpaired t-test unless specified. Data were obtained from one experimental
replicate per subject for each antibody. ↓, significant decrease compared
with non-IPF; ↑, significant increase compared with non-IPF. *P<0.05.
†Mann–Whitney U-test.
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compared with immature collagen (Fig. S6). The pan-inhibitor of
LOs, β-APN, returned TGF-β-induced collagen remodelling to
baseline. In addition, the LOXL2-specific inhibitor blocked TGF-β-
induced remodelling of fibrillar collagen; remodelling levels in the
presence of either inhibitor without TGF-β were not different
compared with control (Fig. 4D). Primary IPF lung fibroblasts
seeded into decellularized normal matrices did not remodel the
fibrillar collagen in the presence of TGF-β (Fig. 4D).
Inhibition of LO activity reduced TGF-β-induced stiffening in
reseeded decellularized matrices
To confirm the functional significance of TGF-β-induced collagen
remodelling in the decellularized matrices reseeded with non-IPF
cells, tissue stiffness (elastic modulus) was measured by atomic
force microscopy (AFM; micro-indentation). TGF-β induced a
significant increase in tissue stiffness that was inhibited by the pan-
inhibitor of LOs, β-APN (Fig. 5). Individual stiffness measurements
Fig. 2. Collagen organization and lysyl
oxidase family of enzymes are
differentially expressed and interrelate
differently in IPF. (A) Representative IHC
images of lysyl oxidase enzymes in the
lungs. Images are representative of lung
tissues from non-IPF (n=10) and IPF (n=8)
subjects (brown, protein of interest; blue,
nucleus; pink, cytoplasm; scale bar:
200 µm). (B) The ratio of LOX and LOXL1
percentage surface area obtained by
image analysis of IHC-stained lung tissues
of non-IPF (n=10; open circles) compared
with IPF (n=8; filled diamonds) subjects;
data were analysed with Student’s two-
tailed parametric unpaired t-test.
(C) Correlation of the ratio of LOX and
LOXL1 with F/B ratio obtained through
image analysis of SHGmicroscopy images
of collagen structure in non-IPF (n=7) and
IPF (n=8) subjects (P<0.0001; R2=0.7527;
average of three or four samples per
subject). (D) 3D scatter plot of collagen
organization (intensity F/B, i.e. SHG
intensity forward/backward signal ratio),
LOXL1 and LOXL2 expression (open
circles, non-IPF, n=7; filled circles, IPF,
n=8). (E) Scree plot showing the number of
relationship groups needed to explain the
associations within measured variables in
non-IPF and IPF tissues (eigenvalue
threshold≥1). (F,G) Weighted average
values of the variables contributing to each
relationship group; comparing non-IPF with
IPF subjects (average of three or four
samples per subject); data were analysed
with Student’s two-tailed parametric
unpaired t-test. Data are presented as
means±s.d. Data were obtained from one
experimental replicate per subject.
*P<0.05, **P<0.01, ***P<0.005.
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for each patient segregated by treatment can be found in Fig. S7, and
representative force curves used to measure stiffness can be found in
Fig. S8C.
DISCUSSION
Although increased collagen deposition is well appreciated in
fibrotic lung tissues, this study identifies, for the first time,
alterations in the fibrillar organization of the collagen fibres in
IPF lung tissue. In addition, this study reports that LOXL1 and
LOXL2 gene and protein levels are increased in the lungs of IPF
compared with non-IPF subjects, with a positive correlation
between increased protein expression and increased fibrillar
collagen organization.
These findings show the complex interrelationship between LOs
and collagen structure and provide further support for focusing on
LO inhibition as a potential therapeutic approach in IPF. Indeed,
LOXL2 inhibition prevented and even reversed bleomycin-induced
pulmonary fibrosis in mice (Barry-Hamilton et al., 2010). In
addition, LOX and LOXL2 were also found to be elevated in liver
fibrosis (Barry-Hamilton et al., 2010; Vadasz et al., 2005) and
were associated with increased deposition of collagen around
the hepatocytes (Vadasz et al., 2005). Although the recent
clinical trial targeting LOXL2 inhibition (ClinicalTrials.gov
NCT01769196) was halted early because of a lack of efficacy
(Raghu et al., 2017), the present study suggests that targeting
LOXL1 in IPF might be as important as targeting LOXL2.
In the present study, IPF alveoli had higher collagen maturity/
thickness (increased F/B SHG) compared with non-diseased
subjects. It can be postulated that the increased collagen fibre
maturity/thickness contributes to the increased stiffness
characteristic of IPF lungs (Booth et al., 2012). This is supported
by the increased stiffnesses measured in this study in the
decellularized lung scaffolds reseeded with fibroblasts exposed to
TGF-β. In IPF there is augmented TGF-β (Broekelmann et al.,
1991), which induces IPF fibroblasts to produce enhanced ECM
proteins (Westergren-Thorsson et al., 2004), thereby creating a
positive feedback loop. In fact, collagen cross-linking might
account for organ stiffening in a variety of fibrotic diseases. The
results of the present study are also concordant with those of
Kottmann et al. (2015), who demonstrated an altered F/B SHG
signal in IPF compared with non-diseased lungs. Interestingly, the
study by Kottmann et al. (2015) showed a decrease in F/B SHG
between healthy and IPF lungs; this difference might be attributable
to different sampling and analysis protocols in comparison to the
present study. For example, in the study by Kottmann et al. (2015),
the majority of the F SHG signal (numerator in the F/B SHG signal
ratio) from healthy subjects originated from muscular arteries,
whereas the present study excluded such regions from analysis. That
said, neither study identified differences in collagen remodelling
between IPF and other fibrotic interstitial lung diseases.
A potential role of other LO family members, not only LOXL2, in
collagen remodelling in IPF was also highlighted in the present
study. A significant increase in LOXL1 gene and protein expression
in IPF lungs, compared with non-IPF tissues, was observed, with a
positive correlation of protein levels with collagen organization. By
contrast, LOX gene expression was unchanged, whereas the LOX
protein level was decreased in IPF lung, highlighting differential LO
family expression in IPF lung tissue, which is similar to that
reported during tumour progression and metastasis (Erler et al.,
2006; Payne et al., 2005). In concordancewith our findings, a recent
study by Aumiller et al. (2017) also reported increased LOXL1 and
LOXL2 protein levels in IPF lungs compared with healthy lungs. By
contrast, however, they also reported an increased LOX protein level
in IPF (Aumiller et al., 2017). These differential results might be
attributable to the different analysis approaches. Aumiller et al.
(2017) scored the intensity of LO staining in discrete structures of
the lung, whereas in our study we used digitized image analysis to
measure the staining intensity of the whole lung tissue section whilst
controlling for the increased tissue mass in IPF lungs.
Of the LO family enzymes, only the LOXL1 protein level was
increased in IPF compared with non-IPF ILD lungs, indicating that
changes in LOXL1 might be specific to IPF rather than to the
process of fibrosis itself. To our knowledge, this study is the first to
show a difference in the interrelationships of the organization of
collagen, LOX, LOXL1 and LOXL2 enzymes between the lungs of
IPF and non-IPF subjects. This is particularly important, because a
Phase II clinical trial using simtuzumab, a LOXL2-specific inhibitor
[ClinicalTrials.gov NCT01769196 (Raghu et al., 2017)] was
recently terminated early owing to a lack of efficacy. The data
presented in the present study support the continued development of
Table 3. Expression of lysyl oxidase enzymes correlates with the maturity/organization of the fibrillar collagen and other lysyl oxidase enzymes in
lung tissues
Correlation matrix
F/B ratio LOX LOXL1 LOXL2
Area Intensity % Surface area Density % Surface area Density % Surface area Density






















































LOXL2 % Surface area 1.000 0.754
0.001*
Density 1.000
Correlation matrix of IHC staining of the lung tissues from both non-IPF (n=7) and IPF (n=8) subject groups and second harmonic imaging F/B ratios (upper value,
R2 values; lower values, P-values). Data were obtained from one experimental replicate per subject for each antibody. F/B ratio, SHG forward/backward
signal ratio. *P<0.05.
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new therapeutic strategies targeting LOs for IPF, especially focusing
on exploration of the potential of LOXL1-specific inhibitors or
combination approaches.
To understand the role of LOs in the remodelling of collagen
fibres in IPF, two 3D in vitro culture models were used to mimic the
complexity of the matrix in vivo. Interestingly, the decellularized
IPF matrices supported lower primary fibroblast infiltration and
viability compared with non-IPF matrices. Although prior works
(Booth et al., 2012; Parker et al., 2014) are in line with the present
data that decellularized IPF matrices influence cellular phenotype,
previous evaluations had not examined differences in cell
attachment between non-IPF and IPF matrices. Thus, these
observations highlight another difference between IPF and non-
IPF lung matrices that should be investigated as a contributor to the
Fig. 3. Inhibition of lysyl oxidase activity reduces
TGF-β-induced collagen remodelling. Collagen I
hydrogels seeded with primary human lung
parenchymal fibroblasts (250,000 cells ml−1) were
stimulated with TGF-β (10 ng ml−1) to induce a fibrotic
phenotype in the presence or absence of the pan-lysyl
oxidase inhibitor, β-APN (100 µM), or the LOXL2-
specific inhibitor, Compound A (Cmpd A; 300 nM).
Samples were treated for 7 days. At the end of the
treatment period, the samples were formalin fixed and
paraffin embedded. (A) Haematoxylin and Eosin stain
of fibroblasts in collagen gel (blue, nucleus; pink,
cytoplasm and general tissue stain; scale bar: 100 µm)
at day 7. (B) SHG image of collagen gel with fibroblasts
at day 7 (cyan, forward mature/organized collagen;
magenta, cell autofluorescence; scale bar=100 µm).
(C) Representative SHG images of collagen gels with
primary human lung parenchymal fibroblasts treated
with or without TGF-β (10 ng ml−1) in the presence or
absence of Compound A (300 nM) (yellow, backward
immature/disorganized collagen; cyan, forward
mature/organized collagen; scale bar: 20 µm).
(D-G) Quantification of SHG microscopy on collagen I
hydrogels embedded with fibroblasts from non-IPF
(n=5; open circles) and IPF (n=5; filled diamonds)
subjects treatedwith pan-lysyl oxidase inhibitor (β-APN;
D,E) or LOXL2-specific inhibitor (Compound A; F,G).
Data are presented as a percentage of the respective
no-cell control (means±s.d.). (D,F) SHG forward/
backward signal surface area ratio (F/B area); higher
ratio indicates higher amount of mature compared with
immature collagens. (E,G) SHG forward/backward
signal intensity ratio (F/B intensity); higher ratio
indicates greater maturity/thickness level of fibrillar
collagen fibres. Statistical analysis was by two-way
ANOVA with matching and multiple comparisons with
Tukey’s correction. Data are presented as means±s.d.
Datawere obtained from one experimental replicate per
subject. Brightness and contrast have been enhanced
for display purposes only and were applied equally for
all images. *Significant difference compared with BSA
control; δsignificant difference compared with BSA
+Compound A control; ϕsignificant difference compared
with TGF-β alone; and #significant difference between
groups.
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pathogenesis of fibrosis. These findings further highlight the
challenge ahead in finding solutions for repairing the disrupted
ECM in IPF.
In collagen gels, TGF-β induced fibroblast production of mature/
thick collagen fibres, but did not affect the overall maturity/
thickness of the fibres. By contrast, TGF-β did not significantly alter
the amount of mature collagen fibres in decellularized human lung
matrices, whereas overall maturity/thickness was increased. This
apparent paradox might simply be attributable to the model
compositions, in that collagen hydrogels lack the complex ECM
components found in decellularized matrices, components that
might influence cellular responsiveness. Alternatively, the
artificiality of the collagen hydrogel, where collagen fibres are not
in a native structural configuration, leads cells to respond by
depositing and remodelling collagen fibres to attain a native
environment. By contrast, decellularized matrices are composed of
collagen fibres and ECM already in a native configuration, thereby
driving cellular driven ECM remodelling rather than production.
This latter conclusion is supported by the presented data (Figs 4 and
5) showing collagen gel F/B intensity >150% of the no cell control
even in unstimulated conditions, whereas decellularized matrices
were recorded at ∼100% in the same conditions. The differences in
the presence of artificial matrix (collagen hydrogel) and native
matrix (decellularized matrix) support previous findings that the
ECM contributes a very important regulatory control on cellular
behaviour (Booth et al., 2012; Parker et al., 2014).
Fig. 4. Inhibition of lysyl oxidase activity
reduces TGF-β-induced collagen
remodelling. Decellularized non-IPF
matrices reseeded with primary human lung
parenchymal fibroblasts (1×106 cells per
matrix) were stimulated with TGF-β
(10 ng ml−1) to induce a fibrotic phenotype in
the presence or absence of the pan-lysyl
oxidase inhibitor, β-APN (100 µM), or the
LOXL2-specific inhibitor, Compound A (Cmpd
A; 300 nM). Cells were seeded in the matrix
for 24 h before being transferred into separate
tissue culture wells with treatment media for
7 days. Samples were collected at the end of
the treatment period and formalin fixed and
paraffin embedded. (A) Manual cell counts of
cells remaining in supernatant after reseeding
in matrices [n=9; combined data from 4 non-
IPF and 5 IPF fibroblasts (500,000 cells ml−1;
2 ml per matrix) into matrices from one non-
IPF and one IPF subject]. (B) Masson’s
Trichrome stain of fibroblasts reseeded into
decellularized matrices for 7 days (blue,
collagen; pink, cell cytoplasm; scale bar:
100 µm). (C) Representative SHG images of
collagen gels with fibroblasts treated with or
without TGF-β (10 ng ml−1) in the presence of
or absence of Compound A (300 nM) (yellow,
backward immature/disorganized collagen;
cyan, forward mature/organized collagen;
scale bar: 100 µm). (D) Quantification of SHG
microscopy on decellularized non-IPF
matrices reseeded for 7 days with fibroblasts
from control (n=5; open circles) and IPF (n=5;
filled diamonds) subjects treated with β-APN
(100 µM) or Compound A (300 nM) in the
presence or absence of TGF-β (10 ng ml−1).
Data are presented as a percentage of the
respective no-cell control (means±s.d.); SHG
forward/backward signal intensity ratio (F/B
intensity); higher ratio indicates greater
maturity/thickness level of fibrillar collagen
fibres. Statistical analysis was by two-way
ANOVA with matching and multiple
comparisons with Tukey’s correction. Data
are presented as means±s.d. Data were
obtained from one experimental replicate per
subject. Brightness and contrast have been
enhanced for display purposes only and were
applied equally for all images. *Significant
difference compared with BSA control; and
#significant difference between groups.
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Pan-inhibition of LO activity blocked TGF-β-induced collagen
remodelling in both collagen hydrogels and decellularized matrix
systems. By contrast, LOXL2-specific inhibition reduced collagen
fibril maturity/thickness only in IPF fibroblasts and in decellularized
matrices. As this effect was not seen with the pan-inhibitor of LOs, it
is likely that this effect was independent of LOXL2. However, prior
data demonstrate that fibroblasts grown in two-dimensional (2D)
culture express a 50 kDa proteolytically processed form of LOXL2
(Hollosi et al., 2009), rather than the intact 95 kDa LOXL2 enzyme
that is inhibited by Compound A. Although the functional activity of
the LOXL2 50 kDa isoform is unknown, it seems unlikely to account
for the present observations, because Compound Awas able to block
other TGF-β-induced effects in 2D and 3D culture. Additionally, pan-
inhibition of LO activity blocked TGF-β-induced tissue stiffening
in the decellularized matrix system (Fig. 5). Both collagen fibril
maturity/thickness and tissue stiffness were increased by TGF-β
treatment, with both being interrupted in the presence of β-APN.
These data indicate that LO enzymes regulate the TGF-β-induced
increase in collagen fibril maturity/thickness that results in increased
tissue stiffness. The pro-fibrotic features of stiff matrices contribute to
the TGF-β-induced fibrosis with potential feedback mechanisms
through the promotion of latent TGF-β activation (Wipff et al., 2007),
thus contributing to the fibrotic process in IPF.
It is worth noting that the stiffness measured in the reseeded
decellularized matrices (mean 40-60 kPa) was higher than the
values measured in native human lung parenchymal tissue (1.34±
0.36 kPa; Liu et al., 2010) and IPF tissue (16.52±2.25 kPa; Booth
et al., 2012). It has been reported in the literature that the
decellularization method affects the stiffness of acellular tissue
(Melo et al., 2014) and, more generally, that decellularized tissue is
stiffer than normal lung tissue (Giménez et al., 2017), although the
origins of these differences in decellularized versus normal tissue
stiffness remain poorly understood. The reseeded decellularized
matrices did not form alveolar structures in the time span of this
study and were densely packed (Fig. 4B), possibly as a result of lack
of inflation of the tissues, which is not possible within the present
experimental set-up. This tissue structure might more closely mimic
scar tissue or remodelled IPF lung tissue (characterized by
progressive scarring of the lungs) rather than non-diseased lung
tissues. In such a case, this would strengthen the significance
of reseeded decellularized matrices in the study of IPF tissue
remodelling. It should also be noted that β-APN might have non-
cell-induced effects on the stiffness, as the stiffness appears lower in
β-APN-treated non-reseeded matrices than those without β-APN
treatment (∼40 versus ∼60 kPa, respectively; Fig. S7), but the
present experiment was not designed to address this hypothesis.
Overall, this study highlights a potential mechanism for
preventing ongoing fibrotic processes, with LO inhibition
preventing lung fibrogenesis in IPF by blocking fibrillar collagen
organization and subsequent tissue stiffening. This, in turn, might
leave deposited collagen more susceptible to proteolytic
degradation and clearance, although further research is needed to
investigate this possibility. The present findings also highlight the
role of multiple members of the LO family in regulating collagen
cross-linking and the disrupted balance of LOs in the IPF lung.
These findings indicate that selective inhibition of LO enzymes,
such as LOXL1, either alone or in combination with LOXL2




Human lungs were procured with written and informed consent from the
patients or next of kin from non-transplantable donors and IPF patients
undergoing lung transplantation as previously described (Booth et al.,
2012). Approval for all experiments with human lung tissue was provided
by the Ethics Review Committees of the South West Sydney Area Health
Service, St Vincent’s Hospital Sydney, Royal Prince Alfred Hospital
(RPAH), and the University of Sydney Human Research Ethics Committee.
As tissues were de-identified, the University of Michigan Institutional
Review Board deemed this work exempt from oversight. Primary human
lung fibroblast samples used as non-diseased controls (non-IPF) were from
the macroscopically normal regions of lungs from patients with non-small
cell carcinoma (NSCCa). Human lung tissue samples were classified by
pathologist diagnosis. Patient demographics are described in Table S3.
Tissue and cell isolation
Tissue isolation was performed on fresh explanted lung tissues. Human lung
parenchymal tissues were isolated and cut into pieces no bigger than 1 cm3.
These pieces were fixed in 4% formaldehyde (Fronine; Thermo Fisher
Scientific, Waltham, MA, USA). After formaldehyde fixation, isolated lung
tissues were embedded in paraffin.
Fig. 5. Inhibition of lysyl oxidase activity reduces TGF-β-
induced stiffening of reseeded decellularized matrices.
Decellularized non-IPF matrices reseeded with primary human
lung parenchymal fibroblasts (106 cells per matrix) were
stimulated with TGF-β (10 ng ml−1) in the presence or absence
of the pan-lysyl oxidase inhibitor, β-APN (100 µM). Cells were
seeded in the matrix for 24 h before being transferred into
separate tissue culture wells with treatment media for 7 days.
Samples were collected at the end of the treatment period and
fresh frozen in OCT compound (10 µm slices). Box and whiskers
plot of the stiffness (elastic modulus). Stiffness was measured
with AFM, and >100 measurements spread over three areas
were taken per sample. Each n is a single AFM measurement.
Data were obtained from one experimental replicate per subject
per treatment. Statistical analysis was by the Kruskal–Wallis test
with Dunn’s correction. **P<0.01, ****P<0.0001.
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Primary human lung fibroblasts were isolated as previously described
(Krimmer et al., 2012; White et al., 2003) and were grown in growth media
[Dulbecco’s modified Eagle’s medium (DMEM) low glucose (Gibco,
Thermo Fisher Scientific) with 0.025 M HEPES (Gibco), 0.375% sodium
hydrogen carbonate (Ajax Finechem, Thermo Fisher Scientific), 10% (v/v)
FBS (JRH Biosciences, Brooklyn, Victoria, Australia) and 1% (v/v)
antibiotics (Invivogen, San Diego, CA, USA), pH 7.1-7.2]. All fibroblast
cell lines were tested for mycoplasma contamination after cell isolation and
culture. For experiments, mycoplasma-free fibroblasts were used between
the third and ninth passages.
In vitro cell culture
Primary human lung fibroblasts were grown in growth media [DMEM low
glucose (Gibco) with 0.025 M HEPES (Gibco) and 0.375% sodium
hydrogen carbonate (Ajax Finechem, Thermo Fisher Scientific)] incubated
in a humidified CO2 incubator (5% CO2 in air) at 37°C. Growth media were
aspirated from cells every 4 days and replaced with fresh growth media until
confluence.
Protein extraction from primary human lung fibroblasts
Whole-cell lysates were prepared using protein extraction buffer [20 mM
Tris (Amresco, Dallas, TX, USA) pH 7.4 with 150 mM sodium chloride
(PanReac Applichem, Darmstadt, Germany), 1 mM EGTA (Sigma, St
Louis, MO, USA), 1 mM EDTA (Amresco), 1 mM sodium fluoride
(NaF; Sigma), 20 mM sodium pyrophosphate (Sigma), 2 mM sodium
orthovanadate (Na3VO4; Sigma), 1% (v/v) Triton X-100 (Sigma), 10% (v/v)
glycerol (Sigma), 0.1% (w/v) SDS (Amresco), 0.5% (w/v) sodium
deoxycholate (Sigma), 1 mM PMSF (Life Technologies, Solon, OH,
USA), 1% (v/v) Protease Inhibitor Cocktail Set III (Calbiochem, San Diego,
CA, USA)] on ice, scraped into a tube, and centrifuged at 150×g for 5 min.
The supernatants were collected and stored at −80°C for further
experiments. Total sample protein was measured using a standard BCA
assay (Sigma).
SHG microscopy
SHG imaging and analysis were performed on paraffin-embedded,
formalin-fixed lung tissue sections as previously published (Tjin et al.,
2014).
Thirty-micrometre-thick samples were used for SHG analysis in human
tissue samples (cohort 1, non-IPF=7 versus IPF=8; and cohort 2, non-IPF
ILD=8 versus IPF=26) and reseeded decellularized human lung tissue
samples. Five-micrometre-thick tissue samples were used for the SHG in
collagen gel samples, as the softness of the sample prevented the use of
thicker samples because of the unavoidable compression of these samples
during processing. Confocal images were taken at ×63 magnification at
16-bit resolution for both forward and backward propagated SHG signals,
with identical detector configurations for all images taken. Laser power was
measured at the objective before the start of each experiment performed on
different days, and laser power settings were adjusted so that all experiments
use the same laser power (25 mW).
Owing to the heterogeneous nature of the lung tissues, a 10×10 grid was
applied on the human tissue samples using the tile function of the Leica LAS
AF software (Leica, Wetzlar, Germany). Three regions for imaging were
then selected using a random number generator. A 5×5 grid was used on
decellularized tissue samples because of the smaller size of the samples
compared with the size of human lung tissue samples. Collagen gel samples
were more homogeneous, and three regions were randomly selected
for SHG.
In the figures, adjustments of brightness and contrast as indicated in the
figure legends were applied uniformly for every set of images and were used
for display purposes only.
SHG image analysis
Image analysis was performed using Fiji (Schindelin et al., 2012) with
images imported from the LAS AF software (Leica). The stack was
deliberately oversampled by 20% in each direction to ensure that the entirety
of the tissue section was imaged. The confocal 3D imagewas analysed using
the histogram to determine the mean (µ) and s.d. (σ) of the signal for the
image. A threshold of µ+σ was then applied to the image to exclude
background emissions as previously published (Abraham et al., 2012).
The pixel area (the number of pixels with intensity above threshold) and
pixel density (average signal intensity per pixel with intensity above
threshold) was measured for every slice in the image using batch processing.
The total signal intensity (total intensity for all pixels with intensity above
threshold) was determined as the product of the pixel area and density. The
average values for these measurements were calculated for every image in
the stack. The above process was repeated for both forward and backward
propagated data to generate area, intensity and density data for both forward
and backward propagated signals. The ratio of forward to backward signal
was then calculated for area, intensity and density measurements.
Lysyl oxidase gene expression in lung tissues
Two publically available microarray data sets from lung tissue samples of
IPF patients and healthy controls were analysed (GSE48149, non-IPF=9
versus IPF=13; and GSE24206, non-IPF=6 versus IPF=10). Microarray
analysis was conducted using R software version 3.02, using the
Bioconductor-limma package, and normalized using Robust Multi-array
Average (RMA). A Benjamini–Hochberg procedure (false discovery rate)
was undertaken to adjust for multiple testing.
Lysyl oxidase protein expression in lung tissues
Immunohistochemistry was performed using a protocol adapted from Faiz
et al. (2013)with antibodies against LOX (Abcam, Cambridge, UK; ab31238;
www.abcam.com/lox-antibody-ab31238.html, accessed 2 May 2016),
LOXL1 (Novus Biologicals, Littleton, CO, USA; NBP1-82827; www.
novusbio.com/LOXL1-Antibody_NBP1-82827.html, accessed 2 May 2016)
and LOXL2 (Novus Biologicals; NBP1-32954; www.novusbio.com/Lysyl-
Oxidase-Homolog-2-LOXL2-Antibody_NBP1-32954.html, accessed 2 May
2016). Primary antibodies were as follows: LOX (1 µg ml−1), LOXL1
(0.1 µg ml−1) or LOXL2 (1 µg ml−1) and isotype control antibody (same
concentration as the respective primary antibodies). Following washing,
samples were treated with EnVision+ anti-rabbit horseradish peroxidase
(HRP)-conjugated secondary antibody (K4003, Dako, Santa Clara, CA,
USA). After a second wash step, colour development was detected with
3′,3′-diaminobenzidine (DAB; Dako), and the tissues were then
counterstained in ready-to-use Mayer’s Haematoxylin solution (Sigma) for
5 min. Sections were then dehydrated, mounted and coverslipped. All
sections for each primary antigen were stained in the same staining run.
IHC image analysis
Images were captured using aWide-field FL and TLmicroscope ZEISS Axio
Scan.Z1 Slide Scanner (Zeiss, Oberkochen, Germany). The immunostained
tissuewas scanned at ×20 magnification, and a whole brightfield tissue image
was stitched together from the individual serial images using ZEN Software
(Zeiss). All images for each set of immunostaining were captured on the same
day with the same microscope settings to ensure uniformity and accuracy of
quantified image analysis. Fiji ImageJ (Schindelin et al., 2012) was used to
quantify the density and distribution of staining. Colour deconvolution
(Ruifrok and Johnston, 2001) vectors in ImageJ were optimized to ensure
accurate separation of Eosin and DAB. Overlaid thresholded images of Eosin
and DAB were used to measure total tissue surface area. The image analysis
calculated the number of pixels above the threshold within the image (‘area’)
and the average intensity of the pixels above the threshold (‘average
intensity’). Macros were used to batch process the images.
Data were represented as ‘percentage tissue surface area’ (DAB area/total
tissue surface area) and ‘density’ (average intensity calculated for the whole
tissue).
Lysyl oxidase protein expression in cell lysates
Western immunoblot was performed using antibodies against LOX (Abcam;
ab31238; 1:2000), LOXL1 (Novus Biologicals; NBP1-82827; 1:2000) and
LOXL2 (Novus Biologicals; NBP1-32954; 1:2000) using a protocol
adapted from Burgess et al. (2003). Cell lysates were run on 10%
polyacrylamide gels and transferred to polyvinyledene difluoride
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membranes (Merck Millipore, Darmstadt, Germany) and protein blocked
for 1 h in 5% skimmed milk. After washing, samples were treated with
HRP-conjugated secondary antibody (Dako). After a second wash step,
detection was performed using chemiluminsecent reagent Immobilon
Western (Merck Millipore) and bands were analysed using a Kodak
imaging system and CarestreamMI software (Molecular Bioimaging, Bend,
OR, USA). Membranes were stripped and reprobed for GAPDH (Merck
Millipore; 1:5000 dilution) as above as a loading control.
Adjustments of brightness and contrast as indicated in the figure legends
were applied uniformly for every set of images and used for display
purposes only.
Antifibrotic potential of LO activity inhibitors (collagen gel
3D model)
Collagen gel solution was prepared for a final collagen gel concentration of
2 mg ml−1. Briefly, 10% (v/v) of 10× PBS and 10% (v/v) 0.1 M NaOHwere
added to stock rat-tail collagen I (BD Biosciences, Franklin Lakes, NJ, USA)
gel solution and mixed while cooled on ice. DMEM media [DMEM low
glucose (Gibco) with 0.025 MHEPES (Gibco) and 0.375% sodium hydrogen
carbonate (Ajax Finechem)] containing resuspended cells was then added at
higher cell concentration for dilution in the collagen gel solution (final
concentration of 2.5×105 cells ml−1 in the collagen gels). Collagen gel mixed
with cells (n=5 non-IPF, n=5 IPF cell lines and n=1 no-cell control) was
pipetted into a 48-well plate and allowed to set in a humidified CO2 incubator
at 37°C for 2 h. Once the gel had set, the gels were then released from the
wells by gently running a sterile syringe needle around between the gel and
the wall of the wells. Treatment media [Set 1: 0.1% bovine serum albumin
(BSA) ±10 ng ml−1 TGF-β ±0.1 mM β-APN; Set 2: 0.01% DMSO +0.1%
BSA ±10 ng ml−1 TGF-β ±300 nM Compound A (Pharmaxis, Sydney,
Australia)] of the same volume as the gel were pipetted gently on top of the
gels in the wells. The collagen gels were collected at day 7, fixed in 4%
paraformaldehyde solution and paraffin embedded.
Decellularization of human lung tissues
Decellularized tissues from a non-diseased subject and an IPF subject were
prepared as previously described (Booth et al., 2012). Essentially, lung
tissues were sequentially incubated in sterile water, deoxycholic acid
(Sigma), sodium chloride (PanReac) and DNAse (Sigma) to clear cellular
and nuclear materials from the tissues. Tissues were washed three times in
sterile PBS between each step. The resultant acellular tissue was biopsied
using a 12-mm punch and then sliced into 1-mm slices on a vibratome. The
acellular tissues slices were sterilized in peracetic acid (Sigma)/ethanol and
rinsed extensively in sterile PBS. Slices were stored in sterile PBS at 4°C
until use.
Antifibrotic potential of LO activity inhibitors (decellularized
matrix 3D model)
Decellularized lung slices from both non-diseased and IPF subjects were
washed three times in sterile DMEM solution and were subsequently added
to a suspension of 5.0×105 fibroblasts ml−1 in growth media at a ratio of 1
matrix:2 ml of cell solution (n=5 non-IPF, n=5 IPF cell lines and n=1 no-cell
control) up to a maximum of 25 ml of solution in a 50 ml Falcon tube. The
Falcon tubes containing the matrices and cell suspension were mounted on a
suspension mixer (Selby, ThermoFisher Scientific, Waltham, MA, USA)
and constantly rotated at low speed (approximately one rotation every 20 s)
at 37°C for 24 h. The reseeded ECMs were placed in separate wells of a
48-well plate with fresh media [0.01% DMSO +0.1% BSA ±10 ng ml−1
TGF-β (R&D Systems, MN, USA) ±300 nM Compound A or 0.1 mM
β-APN (Sigma)] and incubated at 37°C and 5% CO2. The reseeded
decellularized matrices were collected at day 7; half were fixed in 4%
paraformaldehyde solution for 24 h and paraffin embedded, whereas the
other half were fresh frozen in optimal cutting temperature (OCT)
compound and stored at −80°C.
Tissue stiffness measurements using atomic force microscopy
AFMmeasurements were performed on decellularized human lung matrices
with or without reseeded non-IPF cells. Matrices were embedded in optimal
OCT compound, and 10-µm-thick tissue slices were cryosectioned at−21°C
and mounted on poly-L-lysine-coated glass slides. PBS solution was added
on the tissue slice to avoid drying.
Parenchymal tissue areas were identified under an optical microscope (×200
magnification; Olympus, Tokyo, Japan) and mechanically analysed with a
BioScope Catalyst AFM (Bruker, Billerica, MA, USA). Microindentations
were performed using a 2.5-µm-radius sphere-tipped probe (Novascan, Ames,
IA, USA) with a spring constant determined at ∼100 pN nm−1 by the thermal
fluctuation method (Thundat et al., 1994). For each sample, three randomly
selected areas from three non-consecutive tissue slices were analysed in PBS at
room temperature. Force curves were acquired with MIRO 2.0 (NanoScope
9.1; Bruker) at an indentation rate of 20 μm s−1 and a ramp size of 10 μm at
different points along the parenchymal tissue.More than 100 force curves were
performed per sample (∼35 per area; Fig. S8).
The Young’s modulus, E, was determined by fitting of the force curve by
the Hertz sphere model (Dimitriadis et al., 2002; Hertz, 1881) using
NanoScope Analysis software (Bruker) and considering Poisson’s ratio of
0.4 (Butler et al., 1986).
Statistical analysis
Data were entered and sorted using Microsoft Excel (Microsoft, Redmond,
WA,USA). Sample sizes for comparing IPF versus non-IPFwere determined
based on a previous study (Tjin et al., 2014). Statistical analysis was
performed using GraphPad Prism Version 6 Software (GraphPad, La Jolla,
CA, USA). Data were tested for normal distribution with the D’Agostino and
Pearson omnibus normality test and analysed with Student’s t-test (normally
distributed) or the Mann–Whitney U-test (non-normally distributed) as
appropriate. Kruskal–Wallis and two-way ANOVA statistical analyses were
performed where appropriate. Factor analysis was performed using SPSS
software (IBM, Armonk, NY, USA) using ‘principal axis factoring’
analysing ‘correlation matrix’ and extracting ‘2’ factors from the data set.
Promax rotation was used for the factor analysis, using a regression method
and excluding cases listwise where there were missing data points.
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Giménez, A., Uriarte, J. J., Vieyra, J., Navajas, D. and Alcaraz, J. (2017). Elastic
properties of hydrogels and decellularized tissue sections used in
mechanobiology studies probed by atomic force microscopy. Microsc. Res.
Tech. 80, 85-96.
Guo, Y., Savage, H. E., Liu, F., Schantz, S. P., Ho, P. P. and Alfano, R. R. (1999).
Subsurface tumor progression investigated by noninvasive optical second
harmonic tomography. Proc. Natl. Acad. Sci. USA 96, 10854-10856.
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